A first-in-class intravenous kappa opioid receptor (KOR) agonist, an oral soluble guanylate cyclase (sGC) stimulator, a first-in-class subcutaneous complement C3 inhibitor, and an oral contraceptive comprising a synthetic progesterone (drospirenone) and a plant-based estrogen (estetrol) make up the final group of novel drugs from 2021 that we didn’t cover in our other indication-specific reviews. In 2021, the FDA approved four new drugs for various other indications, from rare diseases to pregnancy prevention.
This article and slide deck explores each in more detail, including but not limited to their:
- mechanisms of action
- target rationale
- disease context
- original patents
- key clinical data
- industry history
request a trial
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.